

**Remarks**

As filed, this application contained 11 claims; however, after entry of this preliminary amendment, only new claim 12 will be pending. Also, by way of this preliminary amendment, Applicant has changed the title of the application to more accurately reflect the claimed subject matter.


The specification fully supports new claim 12, and this claim contains no new matter. That said, Applicant reserves the right to pursue subject matter no longer or not yet claimed in this application in this or another application that claims priority hereto.

Applicant also notes that the language used in parts (b)(i) – (vi) of claim 12 to define the artificial antigen presenting cells of the invention corresponds to that used in the claims pending in the '506 and '983 applications. Due to the importance of this application to the assignee, Androclus Therapeutics, SpA, Applicant respectfully asks that, to the extent those applications are determined to contain allowable subject matter, such information be taken into account during the examination of this case. Also, if any issue exists that can be dealt with appropriately without the need for a formal action and response thereto, the Examiner is encouraged to telephone the undersigned at his/her earliest convenience so that the same may be expeditiously resolved.

Respectfully submitted,

Dated: 7 July 2003

BioTechnology Law Group  
658 Marsolan Avenue  
Solana Beach, CA 92075

By:   
Daniel M. Chambers  
Attorney for Applicant  
Reg. No. 34,561  
Telephone: 858.350.9690  
Facsimile: 858.350.9691